Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review

March 2021 | 49 pages | ID: C0F0273C498EN
GlobalData

Abstracts

Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium’s other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Stoughton, Massachusetts, the US.

Collegium Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
Jan 06,2021: Collegium provides 2021 financial guidance
Nov 05,2020: Collegium reports net income of $11.3 million in the third quarter of 2020
Sep 25,2020: Collegium appoints Rita Balice-Gordon to its Board of Directors
Aug 05,2020: Collegium reports net income of $8.1 million in the second quarter of 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Collegium Pharmaceutical Inc - Key Facts
Collegium Pharmaceutical Inc - Key Employees
Collegium Pharmaceutical Inc - Key Employee Biographies
Collegium Pharmaceutical Inc - Major Products and Services
Collegium Pharmaceutical Inc - History
Collegium Pharmaceutical Inc - Company Statement
Collegium Pharmaceutical Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Collegium Pharmaceutical Inc - Business Description
Product Category: Nucynta
Performance
Product Category: Xtampza ER
Performance
R&D Overview
Collegium Pharmaceutical Inc - Corporate Strategy
Collegium Pharmaceutical Inc - SWOT Analysis
SWOT Analysis - Overview
Collegium Pharmaceutical Inc - Strengths
Collegium Pharmaceutical Inc - Weaknesses
Collegium Pharmaceutical Inc - Opportunities
Collegium Pharmaceutical Inc - Threats
Collegium Pharmaceutical Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 11, 2021: Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
Jan 06, 2021: Collegium provides 2021 financial guidance
Nov 05, 2020: Collegium reports net income of $11.3 million in the third quarter of 2020
Sep 25, 2020: Collegium appoints Rita Balice-Gordon to its Board of Directors
Aug 05, 2020: Collegium reports net income of $8.1 million in the second quarter of 2020
Jul 08, 2020: Collegium Pharmaceutical announces appointment of board of directors
May 07, 2020: Collegium reports first quarter 2020 profitability
Feb 27, 2020: Collegium reports full-year 2019 revenue of $296.7 million
Feb 10, 2020: Collegium Pharmaceutical announces Proposed Convertible Senior Notes Offering
Feb 07, 2020: Assertio to divest US rights to Nucynta to Collegium for $375m

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Collegium Pharmaceutical Inc, Key Facts
Collegium Pharmaceutical Inc, Key Employees
Collegium Pharmaceutical Inc, Key Employee Biographies
Collegium Pharmaceutical Inc, Major Products and Services
Collegium Pharmaceutical Inc, History
Collegium Pharmaceutical Inc, Subsidiaries
Collegium Pharmaceutical Inc, Key Competitors
Collegium Pharmaceutical Inc, Ratios based on current share price
Collegium Pharmaceutical Inc, Annual Ratios
Collegium Pharmaceutical Inc, Annual Ratios (Cont...1)
Collegium Pharmaceutical Inc, Annual Ratios (Cont...2)
Collegium Pharmaceutical Inc, Interim Ratios
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Collegium Pharmaceutical Inc, Performance Chart (2016 - 2020)
Collegium Pharmaceutical Inc, Ratio Charts
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021